Pieris Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Palvella Therapeutics

29/03/2023 14:31

* Pieris Pharmaceuticals Inc  PIRS.OQ  reported a quarterly
adjusted loss of 11 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 23 cents per share.
    * Revenue fell 30.8% to $5.85 million from a year ago;
analysts
expected $6.51 million. 
    * Pieris Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 11 cents​.
    * The mean earnings estimate of analysts had fallen by
about 76.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Pieris Pharmaceuticals Inc shares had risen by 42.3% this
quarter.
    * The company reported a quarterly loss of $8.1 million.
    * Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $7.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 29 at 01:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.23          -0.11          Beat
 Sep. 30 2022      -0.16          -0.13          Beat
 Jun. 30 2022      -0.11          -0.14          Missed
 Mar. 31 2022      -0.11          -0.07          Beat